Frost Radar™: Cell and Gene Therapy Contract Development and Manufacturing Organizations, 2022
Published on: 16-Nov-2022 | SKU: HC03603-NA-MR_27123

Need more details?
$4,950.00
DownloadLink
Need more details?

As cell and gene therapy (CGT) moves from ultra-rare indications to more common indications, manufacturing capabilities will have to expand to support the commercial requirements of these diseases. Contract research organizations (CROs) can play a critical role in long-term genetic analysis and monitor safety and efficacy up to 15 years after treatment. Some organizations double up as hybrid CDMOs and incubators.
They have their own pipelines, but they also partner with other companies to support and accelerate development.

Contract development and manufacturing organizations (CDMOs) and CROs are expanding organically and inorganically to provide end-to-end CGT services. More than 100 companies compete in the CGT CDMO marketplace globally, and most specialize in either cell therapy or gene therapy. Only a handful offer diversified services. CDMOs are increasingly distinguishing themselves from their competitors and have redefined themselves as contract research, development, and manufacturing organizations (CRDMOs) and have integrated themselves into companies’
value chains.

The Frost Radar™ reveals the market positioning of companies in an industry using their Growth and Innovation scores as highlighted in the
Frost Radar™ methodology. The document presents competitive profiles on each of the companies in the Frost Radar™ based on their strengths, opportunities, and a small discussion on their positioning. Frost & Sullivan analyzes hundreds of companies in an industry and benchmarks them across 10 criteria on the Frost Radar™, where the leading companies in the industry are then positioned.

Author: Surbhi Gupta

Strategic Imperative

Growth Environment

Growth Environment (continued)

Frost Radar™: Cell and Gene Therapy CDMOs

Frost Radar™: Competitive Environment

Frost Radar™: Competitive Environment (continued)

AGC Biologics

Catalent

Charles River Laboratories

Lonza

Merck KGaA

Minaris Regenerative Medicine

RoslinCT

Thermo Fisher Scientific

WuXi Advanced Therapies

Strategic Insights

Significance of Being on the Frost Radar™

Frost Radar™ Empowers the CEO’s Growth Team

Frost Radar™ Empowers Investors

Frost Radar™ Empowers Customers

Frost Radar™ Empowers the Board of Directors

Frost Radar™: Benchmarking Future Growth Potential

Frost Radar™: Benchmarking Future Growth Potential

Legal Disclaimer

Frost Radar™: Benchmarking Future Growth Potential 2 Major Indices, 10 Analytical Ingredients, 1 Platform

Growth Index

Growth Index (GI) is a measure of a company’s growth performance and track record, along with its ability to develop and execute a fully aligned growth strategy and vision; a robust growth pipeline system; and effective market, competitor, and end-user focused sales and marketing strategies.

  • Market Share (previous 3 years)
    This is a comparison of a company’s market share relative to its competitors in a given market space for the previous 3 years.
  • Revenue Growth (previous 3 years)
    This is a look at a company’s revenue growth rate for the previous 3 years in the market/industry/category that forms the context for the given Frost Radar™.
  • Growth Pipeline
    This is an evaluation of the strength and leverage of a company’s growth pipeline system to continuously capture, analyze, and prioritize its universe of growth opportunities.
  • Vision and Strategy
    This is an assessment of how well a company’s growth strategy is aligned with its vision. Are the investments that a company is making in new products and markets consistent with the stated vision?
  • Sales and Marketing
    This is a measure of the effectiveness of a company’s sales and marketing efforts in helping it drive demand and achieve its growth objectives.

Innovation Index

Innovation Index (II) is a measure of a company’s ability to develop products/ services/ solutions (with a clear understanding of disruptive Mega Trends) that are globally applicable, are able to evolve and expand to serve multiple markets and are aligned to customers’ changing needs.

  • INNOVATION SCALABILITY
    This determines whether an organization’s innovations are globally scalable and applicable in both developing and mature markets, and also in adjacent and non-adjacent industry verticals.
  • RESEARCH AND DEVELOPMENT
    This is a measure of the efficacy of a company’s R&D strategy, as determined by the size of its R&D investment and how it feeds the innovation pipeline.
  • PRODUCT PORTFOLIO
    This is a measure of a company’s product portfolio, focusing on the relative contribution of new products to its annual revenue.
  • MEGATRENDS LEVERAGE
    This is an assessment of a company’s proactive leverage of evolving, long-term opportunities and new business models, as the foundation of its innovation pipeline.
  • CUSTOMER ALIGNMENT
    This evaluates the applicability of a company’s products/services/solutions to current and potential customers, as well as how its innovation strategy is influenced by evolving customer needs.

Significance of Being on the Frost Radar™

Companies plotted on the Frost RadarTM are the leaders in the industry for growth, innovation, or both. They are instrumental in advancing the industry into the future.

  • GROWTH POTENTIAL
    Your organization has significant future growth potential, which makes it a Company to Action.
  • BEST PRACTICES
    Your organization is well positioned to shape Growth Pipeline™ best practices in your industry.
  • COMPETITIVE INTENSITY
    Your organization is one of the key drivers of competitive intensity in the growth environment.
  • CUSTOMER VALUE
    Your organization has demonstrated the ability to significantly enhance its customer value proposition.
  • PARTNER POTENTIAL
    Your organization is top of mind for customers, investors, value chain partners, and future talent as a significant value provider.

Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.
Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.

As cell and gene therapy (CGT) moves from ultra-rare indications to more common indications, manufacturing capabilities will have to expand to support the commercial requirements of these diseases. Contract research organizations (CROs) can play a critical role in long-term genetic analysis and monitor safety and efficacy up to 15 years after treatment. Some organizations double up as hybrid CDMOs and incubators. They have their own pipelines, but they also partner with other companies to support and accelerate development. Contract development and manufacturing organizations (CDMOs) and CROs are expanding organically and inorganically to provide end-to-end CGT services. More than 100 companies compete in the CGT CDMO marketplace globally, and most specialize in either cell therapy or gene therapy. Only a handful offer diversified services. CDMOs are increasingly distinguishing themselves from their competitors and have redefined themselves as contract research, development, and manufacturing organizations (CRDMOs) and have integrated themselves into companies’ value chains. The Frost Radar™ reveals the market positioning of companies in an industry using their Growth and Innovation scores as highlighted in the Frost Radar™ methodology. The document presents competitive profiles on each of the companies in the Frost Radar™ based on their strengths, opportunities, and a small discussion on their positioning. Frost & Sullivan analyzes hundreds of companies in an industry and benchmarks them across 10 criteria on the Frost Radar™, where the leading companies in the industry are then positioned. Author: Surbhi Gupta
More Information
Deliverable Type Frost Radar
Industries Healthcare
No Index No
Is Prebook No
Podcast No
WIP Number PDD4-01-00-00-00

Frost Radar™: Cell and Gene Therapy Contract Development and Manufacturing Organizations, 2022

HealthcareFrost Radar™: Cell and Gene Therapy Contract Development and Manufacturing Organizations, 2022

A Benchmarking System to Spark Companies to Action-Innovation that Fuels New Deal Flow and Growth Pipelines

RELEASE DATE
16-Nov-2022
REGION
North America
Deliverable Type
Frost Radar
Research Code: PDD4-01-00-00-00
SKU: HC03603-NA-MR_27123
AvailableYesPDF Download
$4,950.00
In stock
SKU
HC03603-NA-MR_27123